These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 16206512)

  • 1. A case-control study of serious autoimmune adverse events following hepatitis B immunization.
    Geier DA; Geier MR
    Autoimmunity; 2005 Jun; 38(4):295-301. PubMed ID: 16206512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case-series of adverse events, positive re-challenge of symptoms, and events in identical twins following hepatitis B vaccination: analysis of the Vaccine Adverse Event Reporting System (VAERS) database and literature review.
    Geier MR; Geier DA
    Clin Exp Rheumatol; 2004; 22(6):749-55. PubMed ID: 15638050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, immunization coverage and determinants of a new kind of Hepatitis B vaccine firstly applied in Ningbo, China.
    Yang S; Ma X; Ni H; Zhou S; Hu D; Shi H; Chen X; Dong H; Xu G
    Hum Vaccin Immunother; 2015; 11(12):2819-26. PubMed ID: 26211419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety of currently licensed hepatitis B surface antigen vaccines in the United States, Vaccine Adverse Event Reporting System (VAERS), 2005-2015.
    Haber P; Moro PL; Ng C; Lewis PW; Hibbs B; Schillie SF; Nelson NP; Li R; Stewart B; Cano MV
    Vaccine; 2018 Jan; 36(4):559-564. PubMed ID: 29241647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A one year followup of chronic arthritis following rubella and hepatitis B vaccination based upon analysis of the Vaccine Adverse Events Reporting System (VAERS) database.
    Geier DA; Geier MR
    Clin Exp Rheumatol; 2002; 20(6):767-71. PubMed ID: 12508767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A review of hepatitis B vaccination.
    Geier MR; Geier DA; Zahalsky AC
    Expert Opin Drug Saf; 2003 Mar; 2(2):113-22. PubMed ID: 12904111
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database.
    Geier DA; Geier MR
    Immunol Res; 2017 Feb; 65(1):46-54. PubMed ID: 27406735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective efficacy of hepatitis B vaccine without HBIG in infants of HBeAg-positive carrier mothers in Thailand.
    Lolekha S; Warachit B; Hirunyachote A; Bowonkiratikachorn P; West DJ; Poerschke G
    Vaccine; 2002 Nov; 20(31-32):3739-43. PubMed ID: 12399203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of co-administered quadrivalent human papillomavirus (HPV)-6/11/16/18 L1 virus-like particle (VLP) and hepatitis B (HBV) vaccines.
    Wheeler CM; Bautista OM; Tomassini JE; Nelson M; Sattler CA; Barr E;
    Vaccine; 2008 Jan; 26(5):686-96. PubMed ID: 18164106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years.
    Gilbert CL; Klopfer SO; Martin JC; Schödel FP; Bhuyan PK
    Hum Vaccin; 2011 Dec; 7(12):1336-42. PubMed ID: 22185811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients.
    el-Reshaid K; al-Mufti S; Johny KV; Sugathan TN
    Vaccine; 1994; 12(3):223-34. PubMed ID: 8165854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I clinical trial in healthy adults of a nasal vaccine candidate containing recombinant hepatitis B surface and core antigens.
    Betancourt AA; Delgado CA; Estévez ZC; Martínez JC; Ríos GV; Aureoles-Roselló SR; Zaldívar RA; Guzmán MA; Baile NF; Reyes PA; Ruano LO; Fernández AC; Lobaina-Matos Y; Fernández AD; Madrazo AI; Martínez MI; Baños ML; Alvarez NP; Baldo MD; Mestre RE; Pérez MV; Martínez ME; Escobar DA; Guanche MJ; Cáceres LM; Betancourt RS; Rando EH; Nieto GE; González VL; Rubido JC
    Int J Infect Dis; 2007 Sep; 11(5):394-401. PubMed ID: 17257877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience.
    Van Den Ende C; Marano C; Van Ahee A; Bunge EM; De Moerlooze L
    Expert Rev Vaccines; 2017 Aug; 16(8):811-832. PubMed ID: 28573913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe Autoimmune Adverse Events Post Herpes Zoster Vaccine: A Case-Control Study of Adverse Events in a National Database.
    Lai YC; Yew YW
    J Drugs Dermatol; 2015 Jul; 14(7):681-4. PubMed ID: 26151783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials.
    Fabrizi F; Dixit V; Messa P; Martin P
    Vaccine; 2012 Mar; 30(13):2295-300. PubMed ID: 22285268
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Further observations on the immune response to recombinant hepatitis B vaccine after administration to aboriginal and Torres Strait Island children.
    Hanna JN; Faoagali JL; Buda PJ; Sheridan JW
    J Paediatr Child Health; 1997 Feb; 33(1):67-70. PubMed ID: 9069048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and immunogenicity of a combined hepatitis B virus-Haemophilus influenzae type B vaccine comprising a synthetic antigen in healthy adults.
    Aguilar-Betancourt A; González-Delgado CA; Cinza-Estévez Z; Martínez-Cabrera J; Véliz-Ríos G; Alemán-Zaldívar R; Alonso-Martínez MI; Lago-Baños M; Puble-Alvarez N; Delahanty-Fernandez A; Juvier-Madrazo AI; Ortega-León D; Olivera-Ruano L; Correa-Fernández A; Abreu-Reyes D; Soto-Mestre E; Pérez-Pérez MV; Figueroa-Baile N; Pérez LH; Rodríguez-Silva A; Martínez-Díaz E; Guillén-Nieto GE; Muzio-González VL
    Hum Vaccin; 2008; 4(1):54-9. PubMed ID: 18441530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a novel mammalian cell-derived recombinant hepatitis B vaccine containing Pre-S1 and Pre-S2 antigens in children.
    Raz R; Dagan R; Gallil A; Brill G; Kassis I; Koren R
    Vaccine; 1996 Feb; 14(3):207-11. PubMed ID: 8920701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety of immunisation and adverse events following vaccination against hepatitis B.
    Duclos P
    Expert Opin Drug Saf; 2003 May; 2(3):225-31. PubMed ID: 12904102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine.
    Shafran SD; Mashinter LD; Lindemulder A; Taylor GD; Chiu I
    HIV Med; 2007 Jul; 8(5):295-9. PubMed ID: 17561875
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.